BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 23077021)

  • 1. Regulated microRNAs in the CSF of patients with multiple sclerosis: a case-control study.
    Haghikia A; Haghikia A; Hellwig K; Baraniskin A; Holzmann A; Décard BF; Thum T; Gold R
    Neurology; 2012 Nov; 79(22):2166-70. PubMed ID: 23077021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential microRNA expression in blood in multiple sclerosis.
    Søndergaard HB; Hesse D; Krakauer M; Sørensen PS; Sellebjerg F
    Mult Scler; 2013 Dec; 19(14):1849-57. PubMed ID: 23773985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomic pattern analysis discriminates among multiple sclerosis-related disorders.
    Komori M; Matsuyama Y; Nirasawa T; Thiele H; Becker M; Alexandrov T; Saida T; Tanaka M; Matsuo H; Tomimoto H; Takahashi R; Tashiro K; Ikegawa M; Kondo T
    Ann Neurol; 2012 May; 71(5):614-23. PubMed ID: 22522477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis.
    Avsar T; Korkmaz D; Tütüncü M; Demirci NO; Saip S; Kamasak M; Siva A; Turanli ET
    Mult Scler; 2012 Aug; 18(8):1081-91. PubMed ID: 22252467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis.
    Kuhle J; Leppert D; Petzold A; Regeniter A; Schindler C; Mehling M; Anthony DC; Kappos L; Lindberg RL
    Neurology; 2011 Apr; 76(14):1206-13. PubMed ID: 21346223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing-remitting multiple sclerosis.
    Honardoost MA; Kiani-Esfahani A; Ghaedi K; Etemadifar M; Salehi M
    Gene; 2014 Jul; 544(2):128-33. PubMed ID: 24792898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated levels of miR-181c and miR-633 in the CSF of patients with MS: A validation study.
    Kramer S; Haghikia A; Bang C; Scherf K; Pfanne A; Duscha A; Kaisler J; Gisevius B; Gold R; Thum T; Haghikia A
    Neurol Neuroimmunol Neuroinflamm; 2019 Nov; 6(6):e623. PubMed ID: 31575652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNAs in the CSF: macro-advance in MS?
    Meinl E; Meister G
    Neurology; 2012 Nov; 79(22):2162-3. PubMed ID: 23077022
    [No Abstract]   [Full Text] [Related]  

  • 9. Exosomal microRNA signatures in multiple sclerosis reflect disease status.
    Ebrahimkhani S; Vafaee F; Young PE; Hur SSJ; Hawke S; Devenney E; Beadnall H; Barnett MH; Suter CM; Buckland ME
    Sci Rep; 2017 Oct; 7(1):14293. PubMed ID: 29084979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis.
    Gandhi R; Healy B; Gholipour T; Egorova S; Musallam A; Hussain MS; Nejad P; Patel B; Hei H; Khoury S; Quintana F; Kivisakk P; Chitnis T; Weiner HL
    Ann Neurol; 2013 Jun; 73(6):729-40. PubMed ID: 23494648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased prevalence of and gene transcription by Chlamydia pneumoniae in cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis.
    Dong-Si T; Weber J; Liu YB; Buhmann C; Bauer H; Bendl C; Schnitzler P; Grond-Ginsbach C; Grau AJ
    J Neurol; 2004 May; 251(5):542-7. PubMed ID: 15164186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.
    Khademi M; Kockum I; Andersson ML; Iacobaeus E; Brundin L; Sellebjerg F; Hillert J; Piehl F; Olsson T
    Mult Scler; 2011 Mar; 17(3):335-43. PubMed ID: 21135023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis.
    Fenoglio C; Cantoni C; De Riz M; Ridolfi E; Cortini F; Serpente M; Villa C; Comi C; Monaco F; Mellesi L; Valzelli S; Bresolin N; Galimberti D; Scarpini E
    Neurosci Lett; 2011 Oct; 504(1):9-12. PubMed ID: 21875645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased cerebrospinal fluid chitotriosidase index in patients with multiple sclerosis.
    Verbeek MM; Notting EA; Faas B; Claessens-Linskens R; Jongen PJ
    Acta Neurol Scand; 2010 May; 121(5):309-14. PubMed ID: 19925532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis.
    Fenoglio C; Ridolfi E; Cantoni C; De Riz M; Bonsi R; Serpente M; Villa C; Pietroboni AM; Naismith RT; Alvarez E; Parks BJ; Bresolin N; Cross AH; Piccio LM; Galimberti D; Scarpini E
    Mult Scler; 2013 Dec; 19(14):1938-42. PubMed ID: 24277735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing-remitting multiple sclerosis.
    Ahlbrecht J; Martino F; Pul R; Skripuletz T; Sühs KW; Schauerte C; Yildiz Ö; Trebst C; Tasto L; Thum S; Pfanne A; Roesler R; Lauda F; Hecker M; Zettl UK; Tumani H; Thum T; Stangel M
    Mult Scler; 2016 Aug; 22(9):1202-14. PubMed ID: 26493127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis.
    Romme Christensen J; Börnsen L; Khademi M; Olsson T; Jensen PE; Sørensen PS; Sellebjerg F
    Mult Scler; 2013 Jun; 19(7):877-84. PubMed ID: 23178691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing.
    Keller A; Leidinger P; Steinmeyer F; Stähler C; Franke A; Hemmrich-Stanisak G; Kappel A; Wright I; Dörr J; Paul F; Diem R; Tocariu-Krick B; Meder B; Backes C; Meese E; Ruprecht K
    Mult Scler; 2014 Mar; 20(3):295-303. PubMed ID: 23836875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrathecal IgM synthesis in pediatric MS is not a negative prognostic marker of disease progression: quantitative versus qualitative IgM analysis.
    Stauch C; Reiber H; Rauchenzauner M; Strasak A; Pohl D; Hanefeld F; Gärtner J; Rostásy KM
    Mult Scler; 2011 Mar; 17(3):327-34. PubMed ID: 21123302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis.
    Muñoz-San Martín M; Gómez I; Quiroga-Varela A; Gonzalez-Del Río M; Robles Cedeño R; Álvarez G; Buxó M; Miguela A; Villar LM; Castillo-Villalba J; Casanova B; Quintana E; Ramió-Torrentà L
    Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36724195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.